Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.

Medical oncology (Northwood, London, England) - 25 Feb 2021

Li Jiazheng, Huang Yan, Zhang Yun, Wen Jingjing, Chen Yanxin, Wang Lingyan, Jiang Peifang, Hu Jianda

Abstract excerpt

Ibrutinib has clear efficacy for activated B-cell-like diffuse large B cell lymphoma (ABC-DLBCL) in previous clinical researches. However, the resistance of Ibrutinib has limited its therapeutic benefit and the potential mechanism remains unclear. This study was aimed to identify potential candidate genes and miRNA targets to overcome Ibrutinib resistance in ABC-DLBCL. First, two expression profiles were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Cell Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to Lymphoma, Large B-Cell, Diffuse

Share to Piperidines

Share to Protein Interaction Maps

Share to Proto-Oncogene Proteins c-bcl-6

Share to Thiazolidinediones

Source

Open in PubMed Open full text

Identifiers

PMID: 33629212
DOI: 10.1007/s12032-021-01470-5
PMCID: PMC7904539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.PMID 33629212Read ↗

Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapySemantic proximity Read ↗

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphomaSemantic proximity Read ↗

Multiple Omics Analysis Reveals E2F5 Predict Prognostic Biomarker in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Large-scale transcriptome data analysis reveals prognostic signature genes for overall survival prediction in diffuse large B cell lymphomaSemantic proximity Read ↗

Identification of prognosis-related genes in Burkitt Lymphoma by integrated bioinformatic analysis.Semantic proximity Read ↗

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map databaseSemantic proximity Read ↗

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphomaSemantic proximity Read ↗

Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.Semantic proximity Read ↗

Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical useSemantic proximity Read ↗

miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.